Prior to joining the firm, Andrew counseled hospitals, pharmaceutical and medical device companies, and Medicare Advantage plans on a range of Medicare and Medicaid regulatory, litigation, and transactional matters. He advised on strategic issues surrounding coverage, reimbursement, and compliance, as well as drug pricing and price reporting. He defended clients in investigations by the U.S. Attorney’s Office and the Department of Health and Human Services Office of Inspector General. He has also appeared before several regulatory tribunals, such as the Provider Reimbursement Review Board and the HCPCS Committee.